Taisho Pharmaceutical Co., Ltd.

Meiji Seika Kaisha, Ltd.

Akira Manaka

Masakazu Sato

Katsuo Hatayama

Yutaka Kawashima

Keiko Takahashi

Masato Kashimura

Eiki Shitara

Tomohiro Sugimoto

Tomoaki Miura

Haruhisa Ogita

Kenichi Kanemoto

Dai Kubota

Madoka Kawamura

Kanako Yamamoto

Naoki Sasamoto

Jun Kurosaka

Ken Chikauchi

Masahiro Kawase

Tomohiro Ozawa

[Object]: To provide a compound having a novel structure effective againstand erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

10a-Azalide compound

Thiazoline derivatives

A thiazoline derivative represented by the formula: ##STR1## [wherein R.sup.1 is cyano, carbamoyl, thiocarbamoyl, morpholinothiocarbonyl, alkylthioimidoyl, amidino, substituted amidino or imidazolin-2-yl, R.sup.2 is alkyl or aralkyl, R.sup.3 is hydrogen or alkyl, R.sup.4 is hydroxyl, alkoxy, substituted alkoxy or amino, l is an integer of 1 to 5] and salts thereof have fibrinogen receptor antagonism and cell adhesion factor antagonism, and are useful as therapeutic agents for ischemic diseases and atherosclerosis diseases, and metastasis inhibitory agents of tumors.

Anilide derivatives

Growing community of inventors

Tokyo, Japan

Akira Manaka